Nkrumah-Elie, global director for external research at ChromaDex, was honored for her commitment to advancing science, diversity, and female leadership.
The new test kit, available to healthcare practitioners, utilizes dried blood spot assay technology, which Chromadex reports is most suitable for accuracy.
Deal includes global commercial license and supply agreement for sales of TRU NIAGEN for products in the medical nutrition and consumer health categories.
Collaboration will focus on screening ChromaDex's natural product libraries against certain biological assays and tumor models with the intent of identifying high value, potentially patentable natural products for specific therapeutic indications.
Continued research supporting product use for specific conditions will help grow consumer awareness and offer long-lasting, added value to the category.
ChromaDex Corp. will enter a three-year marketing deal worth at least $3.5 million with Thorne Research Inc. for ChromaDex's NiagenT—a novel, patented, branded nicotinamide riboside (NR) ingredient.
Upon closing of $6 million deal, NeutriSci International will introduce pTeroPure line in Southeast Asia while ChromaDex focuses on selling and marketing its patented pterostilbene ingredient.
A recent Dateline NBC segment concerning dietary supplements focused on the practice of fraudulent analytical testing practices known as "dry labbing," in which lab results pertaining to the potency and identity of ingredients as labeled are suspected of having been deliberately manipulated or fabricated.
Pleasantville, NJ-based NutraFood Science Delivery System, Inc. (NSDS) has been working tirelessly with nutraceutical customers for the last year to create the perfect delivery system.
The uptick in business for CROs is a positive indication that dietary supplement and functional food companies are doing more research on their products.
Whether companies are involved with suppliments, functional foods, or both, research will become crucial to the bottom line in the future, no matter what.